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requiring DAPT interruption, frequently recommended by non-cardiologists and most
commonly due to minor surgery.
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Background: Prasugrel demonstrated superior efﬁcacy in the reductionof events of acute
coronary syndrome (ACS), clopidogrel-naïve, patients treated with percutaneous coro-
nary intervention (PCI), especially in the diabetic (DM) subgroup. The objective of this
study is to assess the efﬁcacy and safety of switching from dual antiplatelet treatment with
clopidogrel to prasugrel inACSDMpatients being treatedwith everolimus-eluting stents.
Methods: Prospective, observational study conducted in 4 different centers. Patients
were included if they met the ADA criteria for established or increased risk for DM.
Platelet reactivity was measured before PCI and 1 month after with 2 different ana-
lyzers (VerifyNow P2Y12 test and Multiplate ADP-HS test); high on-treatment
platelet reactivity (HTPR) was deﬁned as any of the previously demonstrated values:
VerifyNow PRU >208, inhibition of platelet aggregation (IPA) < 20% or Multiplate
AUC>31. The presence of any complication, especially bleeding events, was recor-
ded both before discharge and at 1-month follow-up.
Results: Ninety-six patients were included: 638 years mean age, 77% male, 72%
hypertensive, 66% hyperlipidemic, 32% smokers (plus 23% ex-smokers), 80% ACS
with positive biomarkers, 58% multivessel disease. Only 16% of patients received
insulin. 15% of patients were diagnosed with diabetes and 21% with increased risk for
DM in the index admission. 10% of patients were previously treated with prasugrel
and 5% were changed back to clopidogrel by their treating physicians. Before the PCI,
71 patients (74%) showed HTPR (67% met the VerifyNow criteria, 37% according to
Multiplate results). At 1 month only 14% of patients showed HTPR; 3 of the 4 patients
on clopidogrel treatment (75%) still showed HTPR. After 1 month follow-up only 5
bleeding events were recorded: one caused by coronary perforation after PCI, one
signiﬁcant groin hematoma, 3 minor bleedings (epistaxis, skin hematomas), without
need of subsequent changes in treatment.
Conclusions: Switching from clopidogrel to prasugrel after stent treatment in ACS
diabetic patients is associated with a signiﬁcant reduction in platelet reactivity without
a relevant increase in bleeding complications.
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Background: CYP2C19 gene polymorphisms affect clopidogrel metabolism resulting
in variability in response. We sought to assess the frequency of CYP2C19 variants andB148 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstraassociation of stent thrombosis (ST) in a series of individuals undergoing percuta-
neous coronary intervention (PCI).
Methods: A case-control study of 10 patients with stent thrombosis and 38 patients
were routinely tested for CYP2C19 gene variants using the Verigene (Nanosphere Inc,
Illinois) and iPLEX assays (Sequenom Inc, San Diego). Patients were genotyped for
three single-nucleotide polymorphisms of the CYP2C19 alleles (*2, *3, *17).
Results: Of 48 patients undergoing gene testing 31(65%, 95%CI: 49%, 78%) carried a
loss-of-function (LOF) CYP2C19 allele. Call rate and concordance was 100% be-
tween the two assays. PCI was performed for acute coronary syndrome in 73% of
patients. In patients with a variant allele, 17(55%) were *2, 11 (35%) were *17, and
3(10%) were both *2 and *17. No patient had the CYP2C19*3 variant. LOF alleles
were present in 80% of patients with ST compared to 61% in patients without ST
(OR¼2.6, 95%CI: 0.5,14). Five patients with a LOF allele, had either a clopidogrel
dose increase or were changed to prasugrel, with no in-stent thrombosis in these
patients.
Conclusions: Carriage of a LOF CYP2C19 allele is associated with a higher odds
ratio of in-stent thrombosis in patients on standard dose clopidogrel, highlighting the
need for routine gene testing. Patients with a LOF allele should have alteration of
P2Y12 inhibitor therapy with either a higher dose of clopidogrel or a switch to pra-
sugrel or ticagrelor.
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Background: The aim of this analysis is to evaluate the bleeding risks of new oral
antiplatelet agents in real life.
Methods: All patients with ACS who underwent PCI during admission from September
2011 to December 2013 were included. Baseline characteristics and follow up were
collected prospectively. Bleeding risk was stratiﬁed according to PLATO deﬁnition.
Results: 869 patients were included with a mean age of 62,7 (SD 10,8). Most were
male (81%). Clinical admission: 40% were NSTEMI, 29,3% STEMI and 30,7% un-
stable angina. Median TIMI score was 3 pts, median GRACE score 124 pts and
median CRUSADE 25,7 pts. Clopidogrel was received 54,5%, prasugrel 32,7% and
ticagrelor 12,8%. CRUSADE score was lower in the prasugrel(p< 0,001) and tica-
grelor (p¼0,04)compared with clopidogrel. After a median follow up of 271 days, 92
(11,6%) bleeding events were detected:6,6% minor bleeding,4% mayor bleeding and
1,6% life threatening bleeding. On multivariate analysis STEMI (HR 2,25; CI95%
1,35-3,75;p¼0,002),prasugrel (HR 2,31;CI95% 1,43-1,72; p¼0,001), age (HR
1,036;CI95% 1,010-1,063;p¼0,006) and reduced creatinine clearance (HR 1,74;
CI95% 1,03-2,85;p¼0,037) predicted bleeding events. After analyzing only mayor
and life threatening events, prasugrel was not signiﬁcantly associated with mayor
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